checkAd

    (EDAP) MKap $56M //Heilung für Prostatakrebs nahe US-Zulassung (Seite 31)

    eröffnet am 01.10.13 22:36:23 von
    neuester Beitrag 04.03.24 14:24:13 von
    Beiträge: 1.134
    ID: 1.186.741
    Aufrufe heute: 0
    Gesamt: 147.329
    Aktive User: 0


    Beitrag zu dieser Diskussion schreiben

     Durchsuchen
    • 1
    • 31
    • 114

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 02.03.15 22:24:28
      Beitrag Nr. 834 ()
      Bilderbuchchart
      Avatar
      schrieb am 27.02.15 15:30:12
      Beitrag Nr. 833 ()
      Antwort auf Beitrag Nr.: 49.067.885 von Scheilko am 13.02.15 20:13:32
      First Clinical Experience of Intra-Operative High Intensity Focused...
      First Clinical Experience of Intra-Operative High Intensity Focused Ultrasound in Patients with Colorectal Liver Metastases: A Phase I-IIa Study

      Published: February 26, 2015

      http://journals.plos.org/plosone/article?id=10.1371/journal.…
      Avatar
      schrieb am 27.02.15 00:12:46
      Beitrag Nr. 832 ()
      läuft ;-)
      Avatar
      schrieb am 26.02.15 22:47:15
      Beitrag Nr. 831 ()
      Starker Schlusskurs 3,84 USD. Morgen knacken wir die 4 USD und lassen sie hinter uns.
      Avatar
      schrieb am 26.02.15 18:12:37
      Beitrag Nr. 830 ()
      Top-News! Ich freu mich!

      Trading Spotlight

      Anzeige
      Nurexone Biologic
      0,4220EUR +2,93 %
      Die bessere Technologie im Pennystock-Kleid?!mehr zur Aktie »
      Avatar
      schrieb am 26.02.15 16:28:51
      Beitrag Nr. 829 ()
      Antwort auf Beitrag Nr.: 49.184.111 von aaahhh am 26.02.15 15:27:41und ich hab nur ne miniatur-posi im depot :( ....sobald die shorts sich wieder zu wort melden heißt es für mich nachkaufen!
      Avatar
      schrieb am 26.02.15 16:22:47
      Beitrag Nr. 828 ()
      Antwort auf Beitrag Nr.: 49.184.120 von Manbearpig am 26.02.15 15:29:15
      Zitat von Manbearpig: 4$ im Pre :eek:


      Streiche Pre!:laugh:
      Avatar
      schrieb am 26.02.15 15:29:15
      Beitrag Nr. 827 ()
      Antwort auf Beitrag Nr.: 49.184.111 von aaahhh am 26.02.15 15:27:414$ im Pre :eek:
      1 Antwort
      Avatar
      schrieb am 26.02.15 15:27:41
      Beitrag Nr. 826 ()
      Antwort auf Beitrag Nr.: 49.183.946 von Wuschelchopf am 26.02.15 15:14:33Na steigenden Kurs natürlich. FFM BID 3,32€
      Gruß aaahhh
      3 Antworten
      Avatar
      schrieb am 26.02.15 15:14:33
      Beitrag Nr. 825 ()
      - news -

      EDAP Expands Product Portfolio With New Urological Stone Lasers
      EDAP TMS SA 22 minutes ago GlobeNewswire


      LYON, France, Feb. 26, 2015 (GLOBE NEWSWIRE) -- EDAP TMS SA (EDAP), the global leader in therapeutic ultrasound, today announced a multi-national strategic OEM partnership with Quanta System, a leading manufacturer of medical lasers for surgical and other applications. Under the agreement, Quanta will manufacture customized urological stone lasers to be sold under the EDAP brand. Additionally, EDAP will continue to distribute Holmium lasers in France and certain North African territories, pursuant to its exclusive agreement with Lumenis in those regions.

      Marc Oczachowski, EDAP's Chief Executive Officer, commented, "The addition of urological stone lasers to EDAP's product portfolio will provide excellent synergy with our existing lithotripsy offering for the treatment of urinary stones. We are excited to partner with Quanta System, the world leader in development and manufacture of stone lasers to bring their cutting-edge technology to urologists and patients and drive incremental growth for our Company. This strategic partnership enables EDAP to offer a complete range of minimally invasive solutions from intracorporeal lithotripsy lasers to extracorporeal shockwave lithotripsy devices, covering the full scope of urinary tract stone indications."

      Oczachowski continued: "With our well-established, worldwide network of fully-owned subsidiaries, dedicated distributors and partners, we are well positioned to maximize our lithotripsy sales activity going forward."

      Paolo Salvadeo, Quanta System's Chief Executive Officer, commented: "We are very happy to partner with EDAP as this new cooperation strengthens our position in the worldwide urology market, where Quanta already enjoys strong market share in laser lithotripsy. Our core solutions for urinary stones represent a real benchmark for the industry, and we are pleased to offer them to EDAP, a dynamic company that shares many similarities with Quanta, and to contribute to their continued success throughout the world."

      About EDAP TMS SA

      EDAP TMS SA markets today Ablatherm(R) for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment, Ablatherm-HIFU is approved and commercialized in Europe as a treatment for prostate cancer and is currently under regulatory review in the U.S. following submission of the Pre-Market Approval Application in February 2013 after the completion of a multi-center U.S. Phase II/III clinical trial under an Investigational Device Exemption (IDE) granted by the FDA. In March 2013, the Company introduced a new innovative HIFU device, the Focal One(R) dedicated to focal therapy of prostate cancer. Focal One(R) is CE marked but is not FDA approved. The Company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment (the Sonolith(R) range) for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and http://www.hifu-planet.com.

      About Quanta System S.p.A.

      Quanta System S.p.A produces lasers and laser systems for a wide range of scientific, medical and industrial applications. Quanta System S.p.A. was founded in 1985. Today, with over twenty years of experience in the design of laser sources, laser systems and specific solutions for the OEM market, it is a global company founded on a myriad of local expertise: Italian creativity and research, the methodology and tradition of the German optics industry, American-style Oriented Marketing, and the successful Spanish distribution model. For more information on Quanta System, please visit http://www.quantasystem.com.

      was denkt ihr was das heute für auswirkungen hat
      4 Antworten
      • 1
      • 31
      • 114
       DurchsuchenBeitrag schreiben


      Investoren beobachten auch:

      WertpapierPerf. %
      -0,40
      +0,88
      0,00
      -3,45
      -6,21
      +0,66
      -5,28
      -0,58
      0,00
      -17,06
      23.04.24 · globenewswire · Edap TMS
      27.03.24 · globenewswire · Edap TMS
      13.03.24 · globenewswire · Edap TMS
      06.03.24 · globenewswire · Edap TMS
      04.03.24 · globenewswire · Edap TMS
      29.02.24 · globenewswire · Edap TMS
      01.02.24 · globenewswire · Edap TMS
      08.01.24 · globenewswire · Edap TMS
      02.01.24 · globenewswire · Edap TMS
      30.11.23 · globenewswire · Edap TMS
      (EDAP) MKap $56M //Heilung für Prostatakrebs nahe US-Zulassung